Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients - PubMed (original) (raw)
Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients
E Okada et al. Cancer Lett. 2001.
Abstract
One hundred and thirty three gastric cancer cases were investigated immunohistochemically to clarify the biological role of survivin in gastric cancer cells using a commercially available anti-survivin antibody (SURV11A). Five gastric cancer cell lines were employed to assess localization of survivin by reverse-transcription-polymerase chain reaction (RT-PCR) Southern blotting, Western blotting and immunofluorescence, signals being found in both nucleus and cytoplasm. Survivin nuclear staining of gastric cancer cells was evident in 109 of 133 cases (82.0%) and associated with a favorable prognosis, being an independent prognosticator on multivariate analysis. Survivin nuclear positivity also correlated with younger age and lower incidence of vessel cancer invasion. In contrast, survivin cytoplasmic positivity was noted in 117 cases (88.0%) and did not correlate with any factor of progression or prognosis. The results indicate that survivin is present in the majority of gastric cancer cells but a nuclear localization may play an important physiological role in hindering tumor progression.
Similar articles
- [Prognostic significance of survivin splicing variants in expression gastric cancer].
Meng H, Dai DJ, Lu CD. Meng H, et al. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 May;8(3):234-6. Zhonghua Wei Chang Wai Ke Za Zhi. 2005. PMID: 16167236 Chinese. - Expression level of wild-type survivin in gastric cancer is an independent predictor of survival.
Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Meng H, et al. World J Gastroenterol. 2004 Nov 15;10(22):3245-50. doi: 10.3748/wjg.v10.i22.3245. World J Gastroenterol. 2004. PMID: 15484293 Free PMC article. - Increased expression of survivin in gastric cancer patients and in first degree relatives.
Yu J, Leung WK, Ebert MP, Ng EK, Go MY, Wang HB, Chung SC, Malfertheiner P, Sung JJ. Yu J, et al. Br J Cancer. 2002 Jul 1;87(1):91-7. doi: 10.1038/sj.bjc.6600421. Br J Cancer. 2002. PMID: 12085263 Free PMC article. - Expression of survivin and caspase-3 in gastric cancer.
Kania J, Konturek SJ, Marlicz K, Hahn EG, Konturek PC. Kania J, et al. Dig Dis Sci. 2003 Feb;48(2):266-71. doi: 10.1023/a:1021915124064. Dig Dis Sci. 2003. PMID: 12643601 Clinical Trial. - Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis.
Liu JL, Gao W, Kang QM, Zhang XJ, Yang SG. Liu JL, et al. PLoS One. 2013 Aug 2;8(8):e71930. doi: 10.1371/journal.pone.0071930. Print 2013. PLoS One. 2013. PMID: 23936532 Free PMC article. Review.
Cited by
- Survivin as a Therapeutic Target for the Treatment of Human Cancer.
Wang Q, Greene MI. Wang Q, et al. Cancers (Basel). 2024 Apr 27;16(9):1705. doi: 10.3390/cancers16091705. Cancers (Basel). 2024. PMID: 38730657 Free PMC article. Review. - The nuclear export protein XPO1 - from biology to targeted therapy.
Azmi AS, Uddin MH, Mohammad RM. Azmi AS, et al. Nat Rev Clin Oncol. 2021 Mar;18(3):152-169. doi: 10.1038/s41571-020-00442-4. Epub 2020 Nov 10. Nat Rev Clin Oncol. 2021. PMID: 33173198 Review. - Differentially localized survivin and STAT3 as markers of gastric cancer progression: Association with Helicobacter pylori.
Pandey A, Tripathi SC, Shukla S, Mahata S, Vishnoi K, Misra SP, Misra V, Mitra S, Dwivedi M, Bharti AC. Pandey A, et al. Cancer Rep (Hoboken). 2018 Jun;1(1):e1004. doi: 10.1002/cnr2.1004. Epub 2018 Jun 1. Cancer Rep (Hoboken). 2018. PMID: 32729225 Free PMC article. - Significant function and research progress of biomarkers in gastric cancer.
Ye DM, Xu G, Ma W, Li Y, Luo W, Xiao Y, Liu Y, Zhang Z. Ye DM, et al. Oncol Lett. 2020 Jan;19(1):17-29. doi: 10.3892/ol.2019.11078. Epub 2019 Nov 11. Oncol Lett. 2020. PMID: 31897111 Free PMC article. Review. - Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.
Büscheck F, Sulimankhil M, Melling N, Höflmayer D, Hube-Magg C, Simon R, Göbel C, Hinsch A, Weidemann S, Izbicki JR, Jacobsen F, Mandelkow T, Blessin NC, Möller-Koop C, Lutz F, Viehweger F, Möller K, Sauter G, Lennartz M, Burandt E, Lebok P, Minner S, Bonk S, Huland H, Graefen M, Schlomm T, Fraune C. Büscheck F, et al. Cancer Med. 2020 Feb;9(4):1409-1418. doi: 10.1002/cam4.2773. Epub 2020 Jan 1. Cancer Med. 2020. PMID: 31893572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials